Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1353377rdf:typepubmed:Citationlld:pubmed
pubmed-article:1353377lifeskim:mentionsumls-concept:C0599779lld:lifeskim
pubmed-article:1353377lifeskim:mentionsumls-concept:C0011570lld:lifeskim
pubmed-article:1353377lifeskim:mentionsumls-concept:C0178601lld:lifeskim
pubmed-article:1353377lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1353377pubmed:issue9lld:pubmed
pubmed-article:1353377pubmed:dateCreated1992-9-2lld:pubmed
pubmed-article:1353377pubmed:abstractTextChronic exposure to mild unpredictable stress (CMS) has previously been found to cause an antidepressant-reversible decrease in the consumption of palatable sweet solutions. There is evidence that the effect of antidepressants in this model is mediated by an increase in transmission at dopamine (DA) synpases. The present study investigated whether another treatment known to increase the functional responsiveness of DA systems, intermittent administration of DA agonists, would have antidepressant-like effects. In three experiments in rats, CMS-induced decreases in sucrose consumption were reversed by three to four twice-weekly injections of quinpirole (100-200 micrograms/kg) or bromocriptine (2.5 mg/kg). The effects lasted for several weeks, and when they waned, could be reinstated by a single additional injection of quinpirole. As with tricyclic antidepressants, the effect of quinpirole was reversed by raclopride, administered acutely immediately prior to a sucrose consumption test; there were no changes in sucrose intake in nonstressed control animals. The results suggest that intermittent administration of DA agonists merits investigation as a novel strategy for the treatment of depression.lld:pubmed
pubmed-article:1353377pubmed:languageenglld:pubmed
pubmed-article:1353377pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1353377pubmed:citationSubsetIMlld:pubmed
pubmed-article:1353377pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1353377pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1353377pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1353377pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1353377pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1353377pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1353377pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1353377pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1353377pubmed:statusMEDLINElld:pubmed
pubmed-article:1353377pubmed:monthMaylld:pubmed
pubmed-article:1353377pubmed:issn0006-3223lld:pubmed
pubmed-article:1353377pubmed:authorpubmed-author:WillnerPPlld:pubmed
pubmed-article:1353377pubmed:authorpubmed-author:PappMMlld:pubmed
pubmed-article:1353377pubmed:authorpubmed-author:MuscatRRlld:pubmed
pubmed-article:1353377pubmed:issnTypePrintlld:pubmed
pubmed-article:1353377pubmed:day1lld:pubmed
pubmed-article:1353377pubmed:volume31lld:pubmed
pubmed-article:1353377pubmed:ownerNLMlld:pubmed
pubmed-article:1353377pubmed:authorsCompleteYlld:pubmed
pubmed-article:1353377pubmed:pagination937-46lld:pubmed
pubmed-article:1353377pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:meshHeadingpubmed-meshheading:1353377-...lld:pubmed
pubmed-article:1353377pubmed:year1992lld:pubmed
pubmed-article:1353377pubmed:articleTitleAntidepressant-like effects of dopamine agonists in an animal model of depression.lld:pubmed
pubmed-article:1353377pubmed:affiliationDepartment of Psychology, City of London Polytechnic, England.lld:pubmed
pubmed-article:1353377pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1353377pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1353377lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1353377lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1353377lld:pubmed